BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...
The last three decades have seen significant progress in our understanding of the role of the pro-survival protein BCL-2 and its family members in apoptosis and cancer. BCL-2 and other pro-survival ...
Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
Pharmacodynamic-Guided Modified Continuous Reassessment Method–Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors The specific targeting of diseases, particularly cancer, is a ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...
Use of tumor-mediated TRAIL-receptor expression to evaluate apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. SPARC microenvironment signature (SMS) in patients ...
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic ...
Scientists are developing therapies to eliminate chemotherapy-induced senescent 'zombie' cells, which may fuel inflammation and cancer relapse. These approaches include repurposing existing cancer ...
Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
Fochon Pharmaceuticals Ltd., a subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd., out-licensed FCN-338, a BCL-2 inhibitor, to Eli Lilly and Co. for an up-front payment of $40 million along with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results